Overview

The Anti-fibrotic Therapeutic Effects of Resveratrol for Discharged COVID-19 Patients

Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
A randomized controlled trial (RCT) will be conducted to evaluate the anti-fibrotic therapeutic effects of resveratrol on the clinical symptoms in discharged COVID-19 patients.
Phase:
N/A
Details
Lead Sponsor:
Hong Kong Baptist University
Collaborator:
Hospital Authority, Hong Kong
Treatments:
Resveratrol